Sat, Jan 31, 2015, 11:14 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan Jul 25, 2013 11:38 PM Flag

    Buying opportunity coming again

    People who bought shares of VRTX after it corrected in price following the VX 809/770 trial data restatement, have been well rewarded as the CF franchise has been the focus of wall street's valuation of VRTX future growth. Hepatitis C has been a way to fund the rest of the Vertex pipeline, but is not the driver of most of the future projected growth of the company, even before the safety concern of VX 135 was revealed today. While VX 135 still may work out and get some piece of the hep C market in the years to come, it is the CF franchise that will pay investors next year, and any pull back will be another entry point for those investors with a little patience. Deals to monetize/license the development of VX 787 and 509 are soon to be revealed along with data allowing expansion of VX 770 monotherapy to treat thousands more CF patients. Phase 3 enrollment in VX809 /770 trials is in high gear, and will likely finish 6 months of treatment by the end of the first quarter of 2014. A NDA submission by June 2014, and with breakthrough drug designation allowing quicker approval by the FDA and sales to start in the second half of 2014 to treat half the patients with CF in the US with EU approval to likely follow quickly. Any pullback in the next few days will certainly be a buying opportunity that will pay off once again in the next twelve months.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
110.14-4.00(-3.50%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.